ABL regulation by AXL promotes cisplatin resistance in esophageal cancer

Jun Hong, Dunfa Peng, Zheng Chen, Vikas Sehdev, Abbes Belkhiri

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Esophageal adenocarcinoma (EAC) is characterized by resistance to chemotherapy and poor outcome. Although cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance remains a major clinical problem. The AXL receptor tyrosine kinase, originally isolated as a transforming gene from leukemia, is overexpressed in several solid tumors. Herein, we assessed AXL protein expression in human EACs and examined its role in CDDP resistance in human EAC cells. AXL overexpression was detected in more than 50% of tumors examined. Elevating AXL in nonoverexpressing cells doubled the CDDP IC50 and increased cell survival three-fold, while attenuating AXL in overexpressing cells reduced survival two-fold. The effects of AXL modulation on cell survival were associated with changes in cellular and molecular markers of apoptosis. Mechanistic investigations revealed that AXL blocked CDDP-induced activation of endogenous p73β (TP73), reducing its protein half-life, and inhibited CDDP-induced levels of p-c-ABL(Y412) and p-p73β(Y99). These changes were associated with a disruption of c-ABL/p73β protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73β in response to DNA damage. Together, our results establish that AXL promotes CDDP resistance in esophageal adenocarcinoma and argue that therapeutic targeting of AXL may sensitize these cancers to DNA-damaging drugs.

Original languageEnglish (US)
Pages (from-to)331-340
Number of pages10
JournalCancer Research
Volume73
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Cisplatin
Adenocarcinoma
Cell Survival
Neoplasms
Receptor Protein-Tyrosine Kinases
Oncogenes
Inhibitory Concentration 50
DNA Damage
Half-Life
Cytoplasm
Leukemia
Proteins
Phosphorylation
Apoptosis
Drug Therapy
DNA
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. / Hong, Jun; Peng, Dunfa; Chen, Zheng; Sehdev, Vikas; Belkhiri, Abbes.

In: Cancer Research, Vol. 73, No. 1, 01.01.2013, p. 331-340.

Research output: Contribution to journalArticle

Hong, Jun ; Peng, Dunfa ; Chen, Zheng ; Sehdev, Vikas ; Belkhiri, Abbes. / ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. In: Cancer Research. 2013 ; Vol. 73, No. 1. pp. 331-340.
@article{9741b978f95e41e680d0b9c145a84ac6,
title = "ABL regulation by AXL promotes cisplatin resistance in esophageal cancer",
abstract = "Esophageal adenocarcinoma (EAC) is characterized by resistance to chemotherapy and poor outcome. Although cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance remains a major clinical problem. The AXL receptor tyrosine kinase, originally isolated as a transforming gene from leukemia, is overexpressed in several solid tumors. Herein, we assessed AXL protein expression in human EACs and examined its role in CDDP resistance in human EAC cells. AXL overexpression was detected in more than 50{\%} of tumors examined. Elevating AXL in nonoverexpressing cells doubled the CDDP IC50 and increased cell survival three-fold, while attenuating AXL in overexpressing cells reduced survival two-fold. The effects of AXL modulation on cell survival were associated with changes in cellular and molecular markers of apoptosis. Mechanistic investigations revealed that AXL blocked CDDP-induced activation of endogenous p73β (TP73), reducing its protein half-life, and inhibited CDDP-induced levels of p-c-ABL(Y412) and p-p73β(Y99). These changes were associated with a disruption of c-ABL/p73β protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73β in response to DNA damage. Together, our results establish that AXL promotes CDDP resistance in esophageal adenocarcinoma and argue that therapeutic targeting of AXL may sensitize these cancers to DNA-damaging drugs.",
author = "Jun Hong and Dunfa Peng and Zheng Chen and Vikas Sehdev and Abbes Belkhiri",
year = "2013",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-12-3151",
language = "English (US)",
volume = "73",
pages = "331--340",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - ABL regulation by AXL promotes cisplatin resistance in esophageal cancer

AU - Hong, Jun

AU - Peng, Dunfa

AU - Chen, Zheng

AU - Sehdev, Vikas

AU - Belkhiri, Abbes

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Esophageal adenocarcinoma (EAC) is characterized by resistance to chemotherapy and poor outcome. Although cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance remains a major clinical problem. The AXL receptor tyrosine kinase, originally isolated as a transforming gene from leukemia, is overexpressed in several solid tumors. Herein, we assessed AXL protein expression in human EACs and examined its role in CDDP resistance in human EAC cells. AXL overexpression was detected in more than 50% of tumors examined. Elevating AXL in nonoverexpressing cells doubled the CDDP IC50 and increased cell survival three-fold, while attenuating AXL in overexpressing cells reduced survival two-fold. The effects of AXL modulation on cell survival were associated with changes in cellular and molecular markers of apoptosis. Mechanistic investigations revealed that AXL blocked CDDP-induced activation of endogenous p73β (TP73), reducing its protein half-life, and inhibited CDDP-induced levels of p-c-ABL(Y412) and p-p73β(Y99). These changes were associated with a disruption of c-ABL/p73β protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73β in response to DNA damage. Together, our results establish that AXL promotes CDDP resistance in esophageal adenocarcinoma and argue that therapeutic targeting of AXL may sensitize these cancers to DNA-damaging drugs.

AB - Esophageal adenocarcinoma (EAC) is characterized by resistance to chemotherapy and poor outcome. Although cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance remains a major clinical problem. The AXL receptor tyrosine kinase, originally isolated as a transforming gene from leukemia, is overexpressed in several solid tumors. Herein, we assessed AXL protein expression in human EACs and examined its role in CDDP resistance in human EAC cells. AXL overexpression was detected in more than 50% of tumors examined. Elevating AXL in nonoverexpressing cells doubled the CDDP IC50 and increased cell survival three-fold, while attenuating AXL in overexpressing cells reduced survival two-fold. The effects of AXL modulation on cell survival were associated with changes in cellular and molecular markers of apoptosis. Mechanistic investigations revealed that AXL blocked CDDP-induced activation of endogenous p73β (TP73), reducing its protein half-life, and inhibited CDDP-induced levels of p-c-ABL(Y412) and p-p73β(Y99). These changes were associated with a disruption of c-ABL/p73β protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73β in response to DNA damage. Together, our results establish that AXL promotes CDDP resistance in esophageal adenocarcinoma and argue that therapeutic targeting of AXL may sensitize these cancers to DNA-damaging drugs.

UR - http://www.scopus.com/inward/record.url?scp=84871971116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871971116&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-3151

DO - 10.1158/0008-5472.CAN-12-3151

M3 - Article

C2 - 23117882

AN - SCOPUS:84871971116

VL - 73

SP - 331

EP - 340

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -